Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Non-ST Elevation MI: How Long Do We Have for A Coronary Angiography?

This summary discusses the early invasive strategy and the risk of mortality in non-ST-elevation AMI.


Over the past 2 decades, mortality and complications rates have seen a significant reduction thanks to technological and pharmaceutical development, and the increasing experience of health teams. This is especially true when we look at the use of coronary angiography withing 72 hours of symptom onset; in these cases, mortality risk has gone from 3 to 6 months. 

IAM sin elevación del ST: ¿cuánto tiempo tenemos para realizar una coronariografía?

At present, the information is contradicting when it comes to an early invasive strategy. Even though some registries and randomized studies have not shown improvement, this might be the result of different factors, such as the time between symptom onset and the coronary angiography. 

The KAMIR-NIH with 5856 non-ST myocardial infarction patients (NSTEMI) was analyzed: 3919 of these patients had a symptom onset to catheter time (StC) of <48 hours (66.9%) and 1937 a >48-hr StC.

Primary end point was all cause mortality at 3 years and secondary end point was the composite of all cause death, repeat MI or rehospitalization for cardiac failure at 3 years. 

Mean age was 64 and over 70% were men. 

Read also: Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients presenting <48 hr. StC more often presented hypertension, diabetes, kidney function deterioration, MI, typical angina, angina after the first episode, less cardiac failure, lower GRACE score and better left ventricular function. 

StC was 17.5 hrs. vs 90.8 hrs.

The presence of left main severe stenosis was 5.6%, 3 vessel disease 19%, 2 vessel lesion 28% and one vessel lesion 45%. PCI was done in 85% of cases, CABG in 1.5% and the rest received optimal medical treatment.   

Primary end point at 3 years was 7.3% vs. 13.4% (3-year adjusted HR: 0.76; 95% CI:0.64-0.91; P = 0.002) for <48 hr. StC patient vs >48 hr StC patients respectively. Secondary end point was also in favor of <48 hr StC (12.2% vs. 19.6% 3-year adjusted HR: 0.84; 95% CI: 0.73-0.96; P=0.015).

Read also: Is it Possible to Reduce DAPT Time in Diabetic Patients?

The use of emergency systems was associated to <48 hr StC and lower mortality.

Conclusion

An early invasive strategy based on symptom to catheter time was associated to lower all-cause mortality risk in NSTEMI patients. Seeing as this is a prospective registry, this conclusion should be considered as hypothesis generator to encourage future research. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction.

Reference: SungA Bae, et al. J Am Coll Cardiol Intv 2023;16:64–75.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...

Calcified Nodules and Their Treatment with Rotational Atherectomy

Calcified nodules (CN) represent one of the most complex phenotypes to treat in coronary intervention. They are mainly associated with the need for repeat...

Complex PCI: higher ischemic and bleeding risk in contemporary practice

Advances in pharmacological therapies, equipment, and devices have enabled percutaneous coronary interventions (PCI) to be performed in a growing number of patients with a...

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous closure of paravalvular leaks in high-risk patients: clinical outcomes and the impact of residual leak

Paravalvular leak (PVL) is a relatively frequent complication following valve replacement (overall incidence 5–18%; 2–10% in the aortic position and 7–17% in the mitral...

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...